Tim Craven, Insamo CEO

Ex­clu­sive: Dupix­ent in a pill? Start­up In­samo will try to turn block­buster bi­o­log­ics in­to orals

A new biotech start­up launched Wednes­day to ad­vance a “Goldilocks” ther­a­peu­tic modal­i­ty that could turn some of the in­dus­try’s most lu­cra­tive drugs in­to pills.

Berke­ley, CA-head­quar­tered In­samo was found­ed in 2022 by a trio of PhD sci­en­tists, who have raised a $12 mil­lion seed round that in­cludes in­vestors like ven­Bio and Play­ground Glob­al, CEO Tim Craven told End­points News ex­clu­sive­ly. The board in­cludes Play­ground’s ven­ture part­ner Matt Her­shen­son and is chaired by ven­Bio man­ag­ing part­ner Corey Good­man.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.